Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia

AUTOR(ES)

Oliveira, G.A.P., Costa, E.S., Freitas, M.S., Dutra, F.F., Maia, S.F., Guerra, M.C., Tabernero, M.D., Borojevic, R., Otazu, I.B., Silva, J.L.

FONTE

Brazilian Journal of Medical and Biological Research

DATA DE PUBLICAÇÃO

2010-06

RESUMO

Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.

Documentos Relacionados

• Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
• Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
• Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
• Monitoring imatinib plasma concentrations in chronic myeloid leukemia
• Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital